Key Highlights
- Vector Laboratories merges with Absolute Biotech, enhancing bioconjugation expertise.
- Expanded capabilities to reduce development time for biopharma customers.
- CEO Lisa V. Sellers will lead the combined organization.
- Heather Holemon, CEO of Absolute Biotech, to become Chief Strategy Officer.
- Merger extends manufacturing footprint to the UK and Europe.
Source: Business Wire
Notable Quotes
- “For pharma and biotech customers developing biotherapeutics, particularly antibody-drug conjugates, it’s important that their suppliers can also provide expert guidance in identifying the appropriate solutions to help them succeed. The combination with Absolute Biotech will be a tremendous opportunity to better position Vector Laboratories as a strong partner to biopharma and life sciences companies.”– Lisa V. Sellers, PhD, CEO at Vector Laboratories
- “This merger represents an ideal opportunity to integrate our portfolio of validated, off-the-shelf and custom antibodies with Vector’s best-in-class detection and visualization reagents.” – Heather Holemon, PhD, CEO at Absolute Biotech
SoHC's Take
The merger between Vector Laboratories and Absolute Biotech marks a significant milestone in the life sciences industry. This strategic move not only enhances their product offerings but also expands their global reach, providing customers with more comprehensive solutions. The combined expertise in antibody engineering and bioconjugation will undoubtedly accelerate innovation and development in biotherapeutics, diagnostics, and life sciences tools. With the leadership of Dr. Lisa V. Sellers and the strategic vision of Dr. Heather Holemon, the new entity is well-positioned to address the evolving needs of the biopharma sector and support advancements in healthcare.
